Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Projects Staggering Growth, Surging to $5,099.38 Million by 2030 from $298.75 Million in 2020

In the rapidly evolving field of minimally invasive glaucoma surgery (MIGS), the market has witnessed remarkable growth in recent years. In 2020, the MIGS devices market generated a substantial $298.75 million in revenue. However, the growth trajectory of this market is set to soar even higher, with a projected market size of $5,099.38 million by 2030. This impressive growth is expected to be driven by a robust compound annual growth rate (CAGR) of 35.0% from 2021 to 2030.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.alliedmarketresearch.com/request-sample/4547

The ascent of MIGS devices has revolutionized the treatment of glaucoma, providing patients with safer and less invasive surgical options. The significant surge in market size underscores the increasing adoption of these innovative devices by healthcare professionals and the growing demand for more effective glaucoma management solutions.

As MIGS procedures continue to gain traction, they offer patients numerous advantages over traditional glaucoma surgeries. These procedures are designed to reduce intraocular pressure (IOP) by improving the outflow of aqueous humor, thereby preserving vision and preventing further damage to the optic nerve. The minimally invasive nature of MIGS translates into shorter surgical times, faster recovery periods, and fewer postoperative complications, enhancing the overall patient experience.

Key Market Players

ZIEMER OPHTHALMIC SYSTEMS AG, SANTEN PHARMACEUTICAL CO. LTD., CARL ZEISS MEDITEC AG, NOVARTIS INTERNATIONAL AG (ALCON INC.), ABBVIE INC. (ALLERGAN), IVANTIS INC., ASICO LLC, GLAUKOS CORPORATION, LUMENIS LTD., ISTAR MEDICAL SA

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market

1. By Surgery: a. Glaucoma in Conjunction with Cataract: This segment includes MIGS procedures performed in conjunction with cataract surgery. Since cataracts and glaucoma often coexist, combining the treatments can offer patients improved outcomes and reduced burden of multiple surgeries. b. Stand-Alone Glaucoma: This segment comprises MIGS procedures performed as standalone treatments for glaucoma without the presence of cataracts. Stand-alone MIGS procedures are suitable for patients who do not require cataract surgery or have already undergone cataract removal.

2. By Target: a. Trabecular Meshwork: Trabecular meshwork is a key target in MIGS procedures. The trabecular meshwork is responsible for draining aqueous humor from the eye, and MIGS devices target this area to improve its outflow, reducing intraocular pressure (IOP). b. Suprachoroidal Space: MIGS devices that target the suprachoroidal space aim to enhance the drainage of aqueous humor through this pathway, further aiding in the reduction of IOP. c. Others: This category encompasses additional targets that MIGS devices may focus on, such as the Schlemm's canal, subconjunctival space, or other innovative approaches.

3. By Product: a. MIGS Stents: Stents are small tubes or devices implanted in the eye to create a passage for aqueous humor to flow out, thus reducing IOP. MIGS stents are designed to be minimally invasive and improve the drainage pathways. b. MIGS Shunts: Shunts are implantable devices that create an alternative pathway for aqueous humor drainage, bypassing the natural outflow routes. MIGS shunts can effectively lower IOP by redirecting fluid to reduce pressure within the eye. c. Other (Trabectome/Micro-Implants/Micro-Catheters): This category includes other MIGS devices such as the Trabectome, micro-implants, or micro-catheters that employ different mechanisms to enhance aqueous humor outflow and lower IOP.

4. By End User: a. Eye Hospitals: Eye hospitals are specialized healthcare facilities equipped with advanced infrastructure and resources for comprehensive eye care, including MIGS procedures. b. Ophthalmology Clinics: Ophthalmology clinics focus on diagnosing and treating eye conditions, including glaucoma. These clinics often offer MIGS procedures as part of their services. c. Outpatient Surgical Centers: Outpatient surgical centers provide same-day surgical procedures, including MIGS. These centers offer convenience and cost-effectiveness for patients who do not require overnight hospital stays.

Purchase Premium Copy of Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth Report at: https://www.alliedmarketresearch.com/minimally-invasive-slaucoma-surgery-MIGS-devices-market/purchase-options

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

This release was published on openPR.